TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Skin Blood Flow Changes Using Laser Doppler Imager for Assessment of Pain and Analgesia in Newborn Infants
Brief Summary: The purpose of this study is to assess whether an instrument, the Laser Doppler Imager, is able to measure the effect of pain related changes in skin blood flow in newborn infants. The study will also determine whether the use of sucrose (sugar water) when given by mouth has any effect on pain related skin blood flow changes.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sucrose 24% oral solution | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sterile water | Intervention Type: DRUG; Name: sucrose 24% oral solution; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sterile water; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 25% Sucrose | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: facilitated tucking | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sucrose and facilitated tucking | Intervention Type: PROCEDURE; Name: 25% Sucrose; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: facilitated tucking; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Sucrose and facilitated tucking; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Skin Blood Flow Changes Using Laser Doppler Imager for Assessment of Pain and Analgesia in Newborn Infants
Brief Summary: The purpose of this study is to assess whether an instrument, the Laser Doppler Imager, is able to measure the effect of pain related changes in skin blood flow in newborn infants. The study will also determine whether the use of sucrose (sugar water) when given by mouth has any effect on pain related skin blood flow changes.


Options:
A: Arm Label: Sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sucrose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double distilled water | Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): Sucrose | Intervention Type: DRUG; Name: Double distilled water; Assigned to Arm(s): Placebo
B: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose
C: Arm Label: Kangaroo Mother Care; Type: EXPERIMENTAL; Interventions: Behavioral: Kangaroo Mother Care | Arm Label: Sucrose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Sucrose | Arm Label: Combination Kangaroo Mother Care and Sucrose; Type: EXPERIMENTAL; Interventions: Behavioral: Kangaroo Mother Care, Dietary Supplement: Sucrose | Intervention Type: BEHAVIORAL; Name: Kangaroo Mother Care; Assigned to Arm(s): Combination Kangaroo Mother Care and Sucrose, Kangaroo Mother Care | Intervention Type: DIETARY_SUPPLEMENT; Name: Sucrose; Assigned to Arm(s): Combination Kangaroo Mother Care and Sucrose, Sucrose
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sucrose 24% oral solution | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sterile water | Intervention Type: DRUG; Name: sucrose 24% oral solution; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sterile water; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of 6% Hydroxyethyl Starch (HES, 130/0.4) in Normal Saline Compared to Ringer's Lactate Solution for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section
Brief Summary: The aim of the study is to evaluate the efficacy of Voluven® in the prevention of maternal hypotension in women undergoing spinal anesthesia for cesarean section


Options:
A: Arm Label: ondansetron; Type: EXPERIMENTAL; Interventions: Drug: ondansetron | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ondansetron; Assigned to Arm(s): ondansetron | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 2 ml bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2 ml bupivacaine | Arm Label: 1.5 ml bupivicaine.; Type: ACTIVE_COMPARATOR; Interventions: Drug: 1.5 ml bupivicaine. | Intervention Type: DRUG; Name: 2 ml bupivacaine; Assigned to Arm(s): 2 ml bupivacaine | Intervention Type: DRUG; Name: 1.5 ml bupivicaine.; Assigned to Arm(s): 1.5 ml bupivicaine.
C: Arm Label: Prophylactic ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Normal saline (placebo) control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Prophylactic ephedrine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Normal saline (placebo) control group
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: HES 130/0.4 (6%) in sodium chloride (solution for infusion) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringer's Lactate solution | Intervention Type: DRUG; Name: HES 130/0.4 (6%) in sodium chloride (solution for infusion); Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Ringer's Lactate solution; Assigned to Arm(s): Group B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of 6% Hydroxyethyl Starch (HES, 130/0.4) in Normal Saline Compared to Ringer's Lactate Solution for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section
Brief Summary: The aim of the study is to evaluate the efficacy of Voluven® in the prevention of maternal hypotension in women undergoing spinal anesthesia for cesarean section


Options:
A: Arm Label: 2 ml bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2 ml bupivacaine | Arm Label: 1.5 ml bupivicaine.; Type: ACTIVE_COMPARATOR; Interventions: Drug: 1.5 ml bupivicaine. | Intervention Type: DRUG; Name: 2 ml bupivacaine; Assigned to Arm(s): 2 ml bupivacaine | Intervention Type: DRUG; Name: 1.5 ml bupivicaine.; Assigned to Arm(s): 1.5 ml bupivicaine.
B: Arm Label: Prophylactic ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Normal saline (placebo) control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Prophylactic ephedrine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Normal saline (placebo) control group
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: HES 130/0.4 (6%) in sodium chloride (solution for infusion) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringer's Lactate solution | Intervention Type: DRUG; Name: HES 130/0.4 (6%) in sodium chloride (solution for infusion); Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Ringer's Lactate solution; Assigned to Arm(s): Group B
D: Arm Label: Ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Phenylephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenylephrine | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Ephedrine | Intervention Type: DRUG; Name: Phenylephrine; Assigned to Arm(s): Phenylephrine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy
Brief Summary: The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism \[VTE\] in cancer patients at high risk for VTE and who were undergoing chemotherapy.

The secondary objectives were to evaluate the safety of Semuloparin sodium (AVE5026), to document Semuloparin sodium (AVE5026) exposures, to try identifying a metagene predictor of VTE and to assess the survival status at one year in this population.


Options:
A: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
B: Arm Label: Intermittent Pneumatic Compression(IPC); Type: EXPERIMENTAL; Interventions: Device: pneumatic compression | Arm Label: No Intermittent Pneumatic Compression; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pneumatic compression; Assigned to Arm(s): Intermittent Pneumatic Compression(IPC)
C: Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Imatinib Mesylate; Assigned to Arm(s): N/A
D: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy
Brief Summary: The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism \[VTE\] in cancer patients at high risk for VTE and who were undergoing chemotherapy.

The secondary objectives were to evaluate the safety of Semuloparin sodium (AVE5026), to document Semuloparin sodium (AVE5026) exposures, to try identifying a metagene predictor of VTE and to assess the survival status at one year in this population.


Options:
A: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
B: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): A, B, C
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy
Brief Summary: The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism \[VTE\] in cancer patients at high risk for VTE and who were undergoing chemotherapy.

The secondary objectives were to evaluate the safety of Semuloparin sodium (AVE5026), to document Semuloparin sodium (AVE5026) exposures, to try identifying a metagene predictor of VTE and to assess the survival status at one year in this population.


Options:
A: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
B: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
C: Arm Label: Anticoagulants, aspirin; Type: N/A; Interventions: Drug: Heparin, fondaparinux, vitamin-K antagonists, aspirin | Intervention Type: DRUG; Name: Heparin, fondaparinux, vitamin-K antagonists, aspirin; Assigned to Arm(s): Anticoagulants, aspirin
D: Arm Label: Cohort A - Isoquercetin; Type: EXPERIMENTAL; Interventions: Drug: Isoquercetin | Arm Label: Cohort B - Isoquercetin; Type: EXPERIMENTAL; Interventions: Drug: Isoquercetin | Intervention Type: DRUG; Name: Isoquercetin; Assigned to Arm(s): Cohort A - Isoquercetin, Cohort B - Isoquercetin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy
Brief Summary: The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism \[VTE\] in cancer patients at high risk for VTE and who were undergoing chemotherapy.

The secondary objectives were to evaluate the safety of Semuloparin sodium (AVE5026), to document Semuloparin sodium (AVE5026) exposures, to try identifying a metagene predictor of VTE and to assess the survival status at one year in this population.


Options:
A: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
B: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin, Drug: chemotherapy with LMWH - enoxaparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: only chemotherapy | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: chemotherapy with LMWH - enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: only chemotherapy; Assigned to Arm(s): B
D: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy
Brief Summary: The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism \[VTE\] in cancer patients at high risk for VTE and who were undergoing chemotherapy.

The secondary objectives were to evaluate the safety of Semuloparin sodium (AVE5026), to document Semuloparin sodium (AVE5026) exposures, to try identifying a metagene predictor of VTE and to assess the survival status at one year in this population.


Options:
A: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A
C: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
D: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy
Brief Summary: The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism \[VTE\] in cancer patients at high risk for VTE and who were undergoing chemotherapy.

The secondary objectives were to evaluate the safety of Semuloparin sodium (AVE5026), to document Semuloparin sodium (AVE5026) exposures, to try identifying a metagene predictor of VTE and to assess the survival status at one year in this population.


Options:
A: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
B: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution
C: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
D: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria in Tanzanian Children.
Brief Summary: This trial sets out to determine whether the combination of azithromycin and artesunate (AZ+AS) is as good as the current standard treatment for uncomplicated malaria in Tanzania, artemether-lumefantrine (AL). There are two reasons this is important

1. there are only a limited range of drug combinations which work against malaria in this area of Tanzania
2. azithromycin has antimalarial properties, but is also a broad-spectrum antibiotic, so if the combination is an effective antimalarial it might have a place where there are no diagnostic facilities as syndromic treatment for fever.

Artesunate and azithromycin have both been used alone or in combination with other drugs in children in Tanzania for many years, and are considered safe. There is trial evidence for the effectiveness of this combination in adults in Asia, as well as in-vitro (laboratory) evidence that it works against the malaria parasite.

The trial randomizes children with non-severe malaria to the new combination AZ+AS or the standard care arm AL. The primary outcome is the parasitological failure rate by day 28- meaning do malaria parasites get cleared, and stay cleared for at least 28 days. Secondary outcomes include safety.


Options:
A: Arm Label: Azithromycin + Artesunate; Type: EXPERIMENTAL; Interventions: Drug: azithromycin plus artesunate | Arm Label: Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate | Intervention Type: DRUG; Name: azithromycin plus artesunate; Assigned to Arm(s): Azithromycin + Artesunate | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): Artesunate
B: Arm Label: 1AZ+AQ; Type: EXPERIMENTAL; Interventions: Drug: azithromycin + artesunate | Arm Label: 2AL; Type: ACTIVE_COMPARATOR; Interventions: Drug: artemether-lumefantrine | Intervention Type: DRUG; Name: azithromycin + artesunate; Assigned to Arm(s): 1AZ+AQ | Intervention Type: DRUG; Name: artemether-lumefantrine; Assigned to Arm(s): 2AL
C: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin plus Chloroquine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Artemether-lumefantrine | Intervention Type: DRUG; Name: Azithromycin plus Chloroquine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): 2

Answer: B